Center for Neuropsychiatric Schizophrenia Research, Psychiatric Center Glostrup, University of Copenhagen, Glostrup, Denmark.
Int J Neuropsychopharmacol. 2013 Feb;16(1):23-36. doi: 10.1017/S146114571200003X. Epub 2012 Feb 17.
Studies of in vivo dopamine receptors in schizophrenia have mostly focused on D(2) receptors in striatal areas or on D(1) receptors in cortex. No previous study has examined the correlation between cortical dopamine D(2/3) receptor binding potentials and cognition in schizophrenia patients. The objective was to examine this relation in the frontal cortex in first-episode, drug-naive schizophrenia patients. Based on preclinical and pharmacological evidence, we specifically expected to find a relation between D(2/3) receptor binding potentials and set shifting. This was a cross-sectional, case-control study using single-photon emission computerized tomography with the D(2/3)-receptor ligand [(123)I]epidepride, co-registered with structural magnetic resonance imaging and correlated to cognitive measures. Participants were 24 antipsychotic-naive, first-episode schizophrenia patients and 20 healthy controls matched for gender and age. For patients, a significant linear correlation between D(2/3) BP(ND) and set shifting was found, while significant quadratic associations were observed for verbal fluency, planning and attention. For controls, the only significant association with D(2/3) BP(ND) was a quadratic partial correlation for set shifting. The main findings indicated a relation between D(2/3) receptor binding in the frontal cortex and set shifting, planning and attention, but also support a differential involvement of cortical dopamine D(2/3) receptor binding in at least some cognitive functions, perhaps particularly attention, in schizophrenia patients compared to healthy people. The results suggest that cortical D(2/3) receptor function may be more involved in some cognitive functions (i.e. attention, fluency and planning) in patients with schizophrenia than in healthy people, suggesting that information processing in schizophrenia may be characterized by lower signal:noise ratios.
研究精神分裂症患者体内多巴胺受体主要集中在纹状体区域的 D2 受体或皮质中的 D1 受体。以前没有研究检查过精神分裂症患者皮质多巴胺 D2/3 受体结合势与认知之间的相关性。本研究的目的是在首次发作、未用药的精神分裂症患者的额皮质中检查这种关系。基于临床前和药理学证据,我们特别期望发现 D2/3 受体结合势与转换能力之间存在关系。这是一项使用单光子发射计算机断层扫描与 D2/3-受体配体[(123)I]epidepride 的横断面病例对照研究,与结构磁共振成像共同注册,并与认知测量相关。参与者包括 24 名未经抗精神病药物治疗的首发精神分裂症患者和 20 名匹配性别和年龄的健康对照者。对于患者,发现 D2/3 BP(ND)与转换能力之间存在显著的线性相关性,而在言语流畅性、计划和注意力方面则存在显著的二次关联。对于对照组,与 D2/3 BP(ND) 唯一显著相关的是转换能力的二次偏相关。主要发现表明,额叶皮质中 D2/3 受体结合与转换能力、计划和注意力之间存在关系,但也支持皮质多巴胺 D2/3 受体结合在精神分裂症患者中至少在一些认知功能中存在差异参与,而在健康人中则没有。这些结果表明,与健康人相比,皮质 D2/3 受体功能可能在精神分裂症患者的某些认知功能(如注意力、流畅性和计划)中更为重要,这表明精神分裂症患者的信息处理可能具有较低的信号:噪声比。